Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AstraZenecaAZN -0.28%77 EV-to-EBITDA is 13.68 as of Aug. 20, 2026, which is 21% below its 10-year median of 17.34. GuruFocus rates AZN with a GF Score™ of 77/100 and a GF Value™ of $182.70 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 736 Drug Manufacturers companies, AstraZeneca ranks worse than 50.95% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AstraZeneca's enterprise value is $279,601 Mil.
AstraZeneca's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $20,444 Mil. Therefore, AstraZeneca's EV-to-EBITDA for today is 13.68.
The historical rank and industry rank for AstraZeneca's EV-to-EBITDA or its related term are showing as below:
AZN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.8 Med: 17.34 Max: 53.39
Current: 13.68
During the past 13 years, the highest EV-to-EBITDA of AstraZeneca was 53.39. The lowest was 10.80. And the median was 17.34.
AZN's EV-to-EBITDA is ranked worse than 50.95% of 736
companies
in the Drug Manufacturers industry
Industry Median: 13.305
vs AZN: 13.68
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AstraZeneca's PE Ratio (TTM) for today is calculated as:
AstraZeneca's share price for today is $164.49.
AstraZeneca's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.690.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for AstraZeneca's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, AstraZeneca's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AstraZeneca's EV-to-EBITDA falls into.
AstraZeneca's current Enterprise Value is $279,601 Mil.
AstraZeneca's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $20,444 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca (AZN) has a EV-to-EBITDA of 13.68 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AstraZeneca. This is 21% below median its historical median of 17.34. Over the past decade, AstraZeneca's EV-to-EBITDA has ranged from 10.80 to 53.39. According to the industry distribution chart, AstraZeneca ranks #375 out of 736 companies in the Drug Manufacturers industry, placing it in the top 51%.
Is AstraZeneca's EV-to-EBITDA too high?
AstraZeneca's current EV-to-EBITDA of 13.68 is 21% below median its 10-year median of 17.34. Over the past 10 years, this metric has ranged from a low of 10.80 to a high of 53.39. The Drug Manufacturers industry median EV-to-EBITDA is 13.31. AstraZeneca's value of 13.68 is 2.8% above this industry median. Based on the distribution chart, AstraZeneca ranks #375 out of 736 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AstraZeneca has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, AstraZeneca ranks #375 out of 736 companies for EV-to-EBITDA. This places AstraZeneca in the lower half of its industry. The industry median EV-to-EBITDA is 13.31. AstraZeneca's value of 13.68 is 2.8% above this benchmark. Historically, AstraZeneca's own EV-to-EBITDA has ranged from 10.80 to 53.39 over the past decade. While the company's 10-year median is 17.34 vs. the industry median of 13.31, AstraZeneca has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.31, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca's current EV-to-EBITDA of 13.68 is 2.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AstraZeneca. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca's current EV-to-EBITDA is 13.68, which is 21% below median its own 10-year median of 17.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca (AZN) is currently considered Modestly Undervalued. The stock's GF Value™ is $182.70, compared to a current price of $164.49 — trading 10% below its estimated fair value. The current EV-to-EBITDA is 13.68, which is 21% below median its 10-year median of 17.34 and 2.8% above the Drug Manufacturers industry median of 13.31. AstraZeneca's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For AstraZeneca (AZN), the current EV-to-EBITDA is 13.68 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca (AZN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued.
The current stock price of $164.49 is trading 10% below its estimated GF Value™ of $182.70.
GuruFocus considers AstraZeneca to be Modestly Undervalued.
Key valuation signals for AZN:
EV-to-EBITDA: 13.68 (21% below median its 10-year median of 17.34)
GF Value™: $182.70 vs. price of $164.49 (10% below fair value)
Industry Position: 2.8% above the Drug Manufacturers median (#375 of 736)
No single metric tells the full story. See the AZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
77GF Score
Get the complete analysis for AZN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AZN has been successfully added to your 
